A Study to Evaluate the Safety and Tolerability of Epratuzumab in Patients With Systemic Lupus Erythematosus.
A phase 3, multicenter, open-label, extension study to assess the safety and tolerability of epratuzumab treatment in systemic lupus erythematosus subjects (EMBODY 4)
UCB Inc
1,400 participants
Jul 20, 2011
Interventional
Conditions
Summary
This is a Phase 3, multicenter, open-label, extension study to evaluate the safety, tolerability, efficacy, and immunogenicity of long-term epratuzumab treatment in subjects with SLE. Subjects who complete 1 of the Phase 3, double-blind, placebo controlled studies, SL0009 or SL0010, or terminate prematurely (at Week 16 or later) due to lack of efficacy, are eligible to enroll in SL0012. The study consists of an Open-Label Treatment Period and a Safety Follow-Up Visit. During the Open-Label Treatment Period, all subjects will receive epratuzumab 600mg delivered QW via slow iv infusion for a total of 4 consecutive weeks (CMD 2400mg) over eight 12 week treatment cycles (ie, Weeks 0, 1, 2, 3, 12, 13, 14, 15, 24, 25, 26, 27, 36, 37, 38, 39, 48 (Year 1), 49, 50, 51, 60, 61, 62, 63, 72, 73, 74, 75, 84, 85, 86, and 87 (Year 2) [96 weeks total duration]). A Safety Follow-Up Visit will occur approximately 4 weeks after Week 96 (ie, no later than Week 100) for subjects who complete the study, or 13 weeks after the final dose of study drug for subjects who discontinue early. Study drug treatment is in addition to the subjects’ existing standard care of oral corticosteroids and any immunosuppressants or antimalarials continued from Baseline in the subjects’ prior study.
Eligibility
Inclusion Criteria3
- The subject has completed double-blind study SL0009 (ACTRN12611000464965) or SL0010, or the subject has terminated prematurely at Week 16 or later in SL0009 or SL0010 due to lack of efficacy, as described in the respective protocols and would, in the opinion of the investigator, continue to benefit from continued epratuzumab treatment in SL0012.
- The subject has maintained the eligibility requirements (including concomitant medication restrictions) throughout their participation in the prior study
- Woman of childbearing potential using an acceptable method of birth control
Exclusion Criteria8
- Subject has active, severe, neuropsychiatric SLE, defined as any neuropsychiatric element scoring BILAG level A disease
- Subject has active, severe, SLE disease activity which involves the renal system defined by BILAG renal level A activity
- Evidence of an immunosuppressive state
- Subjects with a history of chronic infections, including but not limited to subjects with concurrent acute or chronic viral hepatitis B or C
- Subjects with substance abuse/dependence or other concurrent medical conditions
- Subjects with significant hematologic abnormalities
- History of malignant cancer
- Subject has used the prohibited medications
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Epratuzumab 600mg intravenous infusions delivered once a week (QW) via slow infusion for a total of 4 consecutive weeks (cumulative dose (CMD) 2400mg) over eight 12-week treatment cycles
Locations(70)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12612000298819